GLG News by Physicians who Treat ADHD (US)

Avaialbe treatments for diabetic neuropathy and other painful neuropathy are much improved over the last 10 years, but more effective ones are in great need

The phase II trial of Glatiramer acetate for ALS fail to show efficacy. This is not unexpected.

Everyone who thinks that the FDA is going to license a vaccine as costly as Gardasil for boys is insane (sorry if I'm being too subtle). Girls get cervical cancer; the rates of penile and anal cancers from HPV is minuscule in comparison. The cost of Gardasil for girls alone is going to strain a...

Huntington's Disease is a tragic hereditary affliction often first manifesting in 30 and 40 year olds, with an autosomal dominant inheritance. Biotechnology is finally catching up with the disease to the extent that there is fundamental research (and drug discovery) underway that can render these offending...

The FDA has approved Abilify for Acute treatment of Manic and Mixed Bipolar I Episodes in 10 to 17 year olds.  The benefit to Otsuka and Bristol Myers will be quite significant in the market for several reasons.  The benefit to kids is more problematic.

The FDA’s approval of Abilify for treatment of acute manic and mixed episodes of pediatric Bipolar Disorder is a very important milestone.   Treatment with Abilify already has had growing off-label use in the pediatric population, in both acute and chronic settings, because of its favorable...

Current medical treatment is far less from being satisfactory

A entirely new concept in curing incurable diseases, such as Huntington's Disease and MS is beginning to show Proof of Concept.  The next several years will witness an exponential rise in research in this arena, as biotechs such as Alnylam (ALNY) and ISIS (ISIS) demonstrate the feasibility of this...

It is only a matter of time, measured in months now, for the Apple Iphone to start treading on Blackberry's Turf.  There are many compelling reasons why this will be inevitable

OCD (Obsessive Compulsive Disorder) and SAD (Social Anxiety Disorder) are two of the more common...much more common than formerly thought...diagnoses and also two of the most difficult to treat.  JAZZ Pharmaceutical's new fluvoxamine formulation (Luvox CR) will invigorate patient self-identification...